Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bivalirudin vs UFH in PCI (ISAR-REACT-3)
NCT00262054Phase 4Completed
- Sponsor
- Deutsches Herzzentrum München
- Start
- Nov 2005
- Primary completion
- Feb 2008
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bivalirudin in coronary artery disease (CAD) and angina pectoris (2 arms), sponsored by Deutsches Herzzentrum München. Primary endpoint: Composite rate of death, myocardial infarction (MI), urgent target vessel revascularization (TVR), or in-hospital major bleeding at 30 days. Started Nov 2005; status: completed.
02
Drugs
bivalirudin
03
Conditions
coronary artery disease (CAD)angina pectoris
Beyond the preview
Go deeper on NCT00262054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00262054.